COX-2s confer QOL benefit in clinical practice in Latin America

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.458, 2004-01, pp. : 3-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

COX-2s confer QOL benefit in clinical practice in Latin America

By  

Inpharma, Vol. 1, Iss. 1448, 2004-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologist's Perspective

By  

Current Topics in Medicinal Chemistry, Vol. 5, Iss. 5, 2005-01 ,pp. : 449-464

Bentham Science Publishers

Access to resources Recommend Favorite

Latin America is the latest region to benefit from Merck & Co.'s antiretroviral price cuts

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 318, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Technology the key to bringing QOL into clinical practice

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 306, 2001-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

COX-2 use grows despite little added benefit over NSAIDs

By  

Reactions Weekly, Vol. 1, Iss. 1037, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite